Replies to post #247475 on Avid Bioservices Inc (CDMO)

[revenue_monster]

CP. that came directly from Shans prepared comments on the July conference call.

[md1225]

Of course the first look will address futility does Bavituximab do something? If the doce taxol arm is trending better then the Bavituximab arm the DMC will recommend stopping trial. Simple as that.

If the Bavituximab arm is overwhelmingly extending life at the first look the DMC may recommend giving all patients Bavituximab.

If the trial is safe and trending as planned the DMC will recommend continuing trial.